Monoclonal antibodies have become an essential tool in biochemistry, molecular biology, and medicine, and basic and clinical investigators have been using them widely for research, diagnosis, and clinical therapy. The Monoclonal Antibodies Facility (MABF) was formally established in 2003. Its main goal is to produce high-affinity antibodies in a high-throughput and effective manner, while concentrating on quality of product and service. The MABF minimizes extensive hands-on procedures and standardizes protocols to provide accurate results and reproducibility.
Specific aims and long-term objectives are: 1) to produce high-affinity custom monoclonal antibodies for a wide range of research projects;2) to enable investigators to access highly-experienced personnel in hybridoma production and methodologies, and trouble-shoot any antigen or screening-related issues;3) to provide quality services at competitive prices;4) to gain insight, by means of the generated antibodies, into the role that different molecules play in normal and pathological systems, and characterize them for eventual therapy or diagnosis. The MABF occupies 726 sq. ft. in SCRB 1, home to the Center for Cancer Immunology Research (CCIR) on the South Campus which is equipped with customized laboratory services, centralized tissue culture rooms, liquid nitrogen tanks rooms, and glassware washing and sterilization facilities, all of which are available to the MABF. The MABF staff consists of Michel Gilliet, MD, Core Leader, is responsible for the direction of the core and chairs the oversight committee. Dr. Gilliet meets with Dr. Bover and Long Vien regularly concerning the overall operation of the MABF. Laura Bover, PhD, Core Co-Leader, is responsible for the overall operation of the MABF, for progress reports, interest researchers in the use of the facility and assures that procedural and policy changes are vetted with the oversight committee. She is responsible together with Long Vien of the short- and long-term planning and growth of the facility. Long Vien, Core Manager, is responsible for the day-to-day operations of the core. Together with Dr. Bover, he plans and designs technical procedures for the different user requirements. James Wygant, Coordinator Research Laboratory, is responsible for technical procedures and makes the first contact with users. He records all activities of the facility and follows-up with users, gathering information pertaining to publications, and grants used to cover the services. Rosa Munoz, Research Assistant, is responsible for technical procedures (hands-on). Future plans are to redesign our website to provide more information on services and benefits in an effort to reach more researchers inside MDACC. The facility also needs to communicate more broadly about the unique value-added features of its services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-37S2
Application #
8530392
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
37
Fiscal Year
2012
Total Cost
$2,882
Indirect Cost
$1,058
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Bose, Prithviraj; Gotlib, Jason; Harrison, Claire N et al. (2018) SOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk 18:1-12
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :
Huang, Shengjian; Jiang, Changying; Zhang, Hui et al. (2018) The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma. Blood Cancer J 8:33
Hwang, Jessica P; Ahmed, Sairah; Ariza-Heredia, Ella J et al. (2018) Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant. Biol Blood Marrow Transplant 24:1094-1098
He, Jing; Huo, Lei; Ma, Junsheng et al. (2018) Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. Am J Clin Pathol 149:253-261
Schembre, Susan M; Liao, Yue; O'Connor, Sydney G et al. (2018) Mobile Ecological Momentary Diet Assessment Methods for Behavioral Research: Systematic Review. JMIR Mhealth Uhealth 6:e11170
Abbas, Hussein A; Bui, Ngoc Hoang Bao; Rajapakshe, Kimal et al. (2018) Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes. Cancer Res 78:451-462
Zhu, Lele; Xie, Xiaoping; Zhang, Lingyun et al. (2018) TBK-binding protein 1 regulates IL-15-induced autophagy and NKT cell survival. Nat Commun 9:2812
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :

Showing the most recent 10 out of 12418 publications